



MicroRNAs association with azoospermia, oligospermia, asthenozoospermia, and teratozoospermia: a systematic review

Yousef Daneshmandpour^{1,2,3,4} · Zahra Bahmanpour^{3,5} · Hamid Hamzeiy^{4,6} · Marziyeh Mazaheri Moghaddam^{3,4,5} · Madiheh Mazaheri Moghaddam⁷ · Bahareh Khademi^{3,5} · Ebrahim Sakhinia^{1,3,4,8}

Received: 19 July 2019 / Accepted: 22 December 2019 / Published online: 18 March 2020
© Springer Science+Business Media, LLC, part of Springer Nature 2020

Abstract

Infertility is a major health problem across the world. One of the main reasons for male infertility are defects in sperm. Semen analysis is the most common test utilized to evaluate male fertility and since it suffers from multiple drawbacks, reproduction scientists have tried to find new molecular markers for detecting sperm defects. MicroRNAs (miRNAs) are small molecules in cells which take part in regulating gene expression. Various studies have confirmed miRNAs to have a role in defining multiple sperm characteristics, including sperm count, motility, and morphology. In this paper, we have systematically reviewed the role of miRNAs in infertile men with sperm defects including azoospermia, oligospermia, asthenozoospermia, and teratozoospermia. Also, we have assembled various bioinformatics tools to come up with a pipeline for predicting novel miRNAs which could possibly participate in sperm count, motility, and morphology. Also, related KEGG and GO terms for predicted miRNAs have been included in order to highlight their role in sperm function. Our study emphasizes the potential role of miRNAs in male infertility and provides a general overview for future studies aiming to find robust molecular markers for this condition.

Keywords MicroRNA · Azoospermia · Oligospermia · Asthenozoospermia · Teratozoospermia · Bioinformatics

Introduction

Infertility, defined as the inability to conceive after one year of unprotected intercourse, is a common reproductive health problem which affects almost 15% of couples globally [1]. Male infertility is responsible for 50% of infertility cases, which can be due to acquired or congenital abnormalities. A considerable proportion of male infertility cases are defined as

“unexplained male infertility” (UMI). Prevalence of UMI ranges from 6 to 37% and includes infertile men with reduced semen quality without a history of fertility-associated problems and normal physical/hormonal examination results [2]. Currently, diagnosis of UMI is restricted to semen analysis which includes quantitative (azoospermia, oligospermia) and qualitative (asthenozoospermia, teratozoospermia) abnormalities [3]. Semen analysis is the backbone of male infertility

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s10815-019-01674-9>) contains supplementary material, which is available to authorized users.

✉ Ebrahim Sakhinia
esakhinia@yahoo.co.uk

¹ Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

² Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

³ Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

⁴ Tabriz Genetic Analysis Centre (TGAC), Tabriz University of Medical Sciences, Tabriz, Iran

⁵ Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

⁶ Genomize Inc., Istanbul, Turkey

⁷ Department of Genetics and Molecular Medicine, School of Medicine, Zanjan University of Medical Sciences (ZUMS), Zanjan, Iran

⁸ Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

evaluation which suffers from multiple drawbacks: (1) normal semen results do not guarantee conception, (2) there is a significant overlap between semen parameters of fertile and infertile men, (3) semen analysis does not provide information about the intracellular functions of sperm [4]. Considering the disadvantages of semen analysis mentioned above, it is of utmost importance to look for new tests and biomarkers in order to diagnose and characterize male infertility.

Spermatogenesis, a complex procedure, contains three main steps: self-renewal and proliferation of spermatogonia, meiotic division of spermatocytes, and postmeiotic differentiation of spermatids into mature spermatozoa [5]. These intricate processes are regulated by the different types of regulatory mechanisms including piwi-interacting RNAs, long non-coding RNAs and microRNAs (miRNAs) [6].

MiRNAs are important regulatory molecules in cells participating in significant cellular processes including embryonic development, cell differentiation, and apoptosis [7, 8]. MiRNAs are non-coding RNAs which consist of 18–24 nucleotides with a single-stranded structure and are generated endogenously in cells [9]. Biosynthesis of miRNAs has been studied widely in a different type of cells. In brief, miRNAs are produced by RNA polymerase II in the nucleus with a hairpin structure called pri-miRNA. This structure is further processed by a member of the RNpAase III enzymes called Drosha resulting in the pre-miRNA. The pre-miRNA is exported to the cytoplasm by exportin-5 and is later processed by Dicer, another member of the RNAase III enzymes, leading to the generation of the mature miRNA. The mature miRNA is loaded to RNA-induced silencing complex (RISC) which represses the expression of target genes by degrading its mRNA or repressing translation [10]. There is a complex interplay between genes and miRNAs, one miRNA can regulate multiple RNAs or one gene can be regulated by multiple miRNAs [11].

Regarding the important role of miRNAs in the cell, dysregulation of miRNAs has been observed in various types of diseases, including infertility [12]. Ostermeier et al. (2004) identified miRNAs in the spermatozoa for the first time [13]. Until now, multiple studies have been conducted to find miRNAs with different expression patterns in infertile males as a new promising biomarker and also elucidate its function in spermatogenesis and fertility; still, many questions remain about the function of miRNAs in sperm cells [14]. In the current study, we have reviewed published research about the role of miRNA in four main sperm abnormality categories including azoospermia, oligospermia, asthenozoospermia, and teratozoospermia. Also, we have used bioinformatics tools to predict novel miRNAs in each category based on reported genes. Results of this study can guide future studies about the role of miRNAs in male infertility.

Methods

Search strategy

The current scoping review was performed according to the PRISMA statement [15]. The following electronic databases were searched in order to identify published articles up to 25 Oct 2019: PubMed, Embase, and Scopus. The search on the google scholar database was conducted to find gray literature. The search strategy for Embase database is shown in the Supplementary Table 1.

Study selection and assessment of studies

Following the aforementioned database search, all resulting papers were loaded into EndNote version X and duplicate studies were removed. Titles and abstracts of the studies were assessed and the full text of the remaining articles were evaluated with the inclusion criteria. The inclusion criteria of this review were studies that analyzed the expression level of miRNAs in reproductive system tissues and fluids (testicular tissue, sperm cells, and seminal plasma and its exosomes) in patients with sperm characteristics defects including azoospermia, asthenozoospermia, oligospermia, and teratospermia.

Data extraction

The required data were extracted using a self-constructed data extraction table. Author and publication year, origin, age and gender of the patients, sperm characteristics of patients, and identified miRNAs were extracted from the studies. The extracted data included identified miRNAs with different expression levels in infertile men with sperm defects.

Bioinformatics tools

In this study, an important and useful database, DisGeNET (<http://www.disgenet.org/>), a database of gene-disease relations, has been used to retrieve the responsible genes in each group of sperm abnormality [16]. Reported genes in each group were used for predicting miRNAs that can potentially have an effect on the phenotype. The miRWalk database (<http://www.ma.uni-heidelberg.de/apps/zmf/mirwalk/>), an open-source database containing both predicted and validated miRNA, was employed to identify miRNAs targeting genes in each sperm abnormality group. Also, other databases in miRWalk including miRDB, PITA, MicroT4, miRMap, RNA22, miRanda, miRNAMap, RNAhybrid, miRBridge, PICTAR2, and TargetsScan were used [17]. Galaxy (<http://usegalaxy.org>) was used to find and select the miRNAs with the highest number of interactions [18].

Galaxy is used to calculate the number of genes targeted by each predicted miRNA. Then miRNAs with the highest

number of target genes were chosen and given to mirPath v.3 to obtain the Kyoto Encyclopedia of Genes and Genomes (KEGG) and gene ontology (GO) terms related to the predicted miRNAs (P value < 0.05) [19]. mirPath v.3 can only process 100 gene/miRNAs at a time, so based on this restriction, we chose the top five miRNAs with the highest number of target genes in each category for analysis (miRNAs with the same number of the target gene were included simultaneously). So, in azoospermia (7 miRNAs and its target genes), OS (9 miRNAs and its target genes), AZS (67 miRNAs and its target genes), and TS (100 miRNAs and its target genes) were included in miRPath v.3, respectively.

Consequently, in order to visualize miRNAs and their target genes, Cytoscape (<https://cytoscape.org/>) was used to visualize the interactions of miRNAs with the highest number of target genes [20]. The pipeline employed in this study has been depicted in Fig. 1.

Results

A total of 165 studies were identified by searching PubMed, Emabase, and proquest databases. After removing duplicated articles, 95 studies remained. Titles and abstracts of the studies were evaluated resulting in 42 studies. The full text of the articles based on our inclusion criteria were evaluated and 33 studies remained for our systematic review.

Between included studies, 18 studies were Chinese [21–38], 6 studies were German [39–44], 3 were Iranian [45–47], 3 were Spanish [48–50], and one study was Egyptian [51] and Dutch [52]. Different samples from urogenital tract and gonads were used in studies including testicular tissue [21, 24–28, 31, 39, 40, 45], sperm cell [22, 23, 32, 33, 38, 42, 43, 46, 47, 49–53], semen exosomes [44, 48], seminal plasma [30, 34–37, 41], and samples from different spermatogenesis steps [29]. The detail of the included studies is summarized in Table 1. Also, the flow chart of the study is depicted in Fig. 2.

Azoospermia

Azoospermia (AZ) is defined as the complete absence of sperm in ejaculated semen; it affects 1% of the male population in the world and is responsible for 10–15% of infertility cases. AZ is clinically divided into two categories, obstructive azoospermia (OA) or non-obstructive azoospermia (NOA) [54, 55]. Genetic factors are responsible for 21–29% of infertility cases in men, but still, 12–41% of AZ cases have unknown etiology which most probably relate to unknown genetic factors [56]. Studies have indicated that different types of genetic disorders are responsible for AZ including chromosomal aberrations, monogenic disorders, multifactorial genetic diseases, epigenetics defects, and genetic abnormalities at the primordial germ cell [57].

Multiple studies have evaluated the role of miRNAs in azoospermic infertile patients. In 2009, for the first time, expression of miRNAs in a testicular sample of NOA patients compared to fertile control samples evaluated by microarray technology, identified 19 upregulated and 154 downregulated miRNAs [21]. *Hsa-miR-141*, *hsa-miR-429*, and *hsa-miR-7-1-3p* expression levels were significantly increased in 100 NOA sperm samples compared to controls [22]. The expression of *let7* and *hsa-miR-30* in azoospermia patients showed higher expression of former while later showed no significant changes [45]. Abu-Halima et al. (2014) evaluated the expression level of miRNAs in four different groups of testicular tissue samples of azoospermic patients with histopathological defects. The results indicated different levels of expression in each group which participate in main cellular functions including apoptosis, cell proliferation, and differentiation [39]. Four downregulated miRNAs (*hsa-miR-34b**, *hsa-miR-34b*, *hsa-miR-34c-5p*, *hsa-miR-122*) and one upregulated miRNA (*hsa-miR-429*) was identified in testicular tissue samples of NOA patients [40]. Based on luciferase experiments *miR-525-3p* targets 3'-untranslated region of *SEMG1* gene and lower expression of this miRNA result in higher expression of *SEMG1* gene in azoospermia patients [23] Zhuang et al. 2015, on NOA and normozoospermic OA patients, identified differential expression of 93 miRNAs and 4172 mRNAs

Fig. 1 Pipeline employed in this study





Table 1 Details of included studies. NOA = non-obstructive azoospermia, obstructive azoospermia = OA, RT-PCR = real-time PCR, not mentioned = NM, upregulation = ↑, downregulation = ↓

Author year	Origin	Age	miRNA measurement technique	Sample type	Studied patients	Identified miRNAs/conclusion	REF
Lian et al. 2009	China	22–30	Microarray assay validation = RT-PCR	Testicular tissue	NOA = 3 Control = 2	Microarray = 19 ↑-154↓ Confirmed with RT-PCR= hsa-hsa-miR-302a, hsa-miR-491-3p, hsa-miR-5204-3p, hsa-miR-383 hsa-miR-141↑, hsa-miR-429↑, hsa-miR-7-1-3p↑ let7↑	[21]
Wu et al. 2013	China	Case = 28.20 ± 4.02 Controls = 29.25 ± 3.03 NM	TaqMan low density array validation = qRT-PCR RT-PCR	Sperm cell Testicular tissue	NOA = 100 Control = 100 NOA = 40 Control = 40 AZ = 56	Hsa-miR-34b*, hsa-mir-34b, hsa-mir-34c-5p, hsa-mir-449a, and hsa-mir-449b (hsa-miR-34b*, hsa-miR-34b, hsa-miR-34c-5p, hsa-miR-122) ↓ Hsa-miR-525-3p ↓	[22]
Khosravi Mashizi et al. 2019	Iran	NM	RT-PCR	Testicular tissue	NOA = 40 Control = 40	Hsa-miR-34b*, hsa-mir-34b, hsa-mir-34c-5p, hsa-mir-449a, and hsa-mir-449b (hsa-miR-34b*, hsa-miR-34b, hsa-miR-34c-5p, hsa-miR-122) ↓	[45]
Abu-Halima et al. 2014	Germany	25.7 ± 3.6	Microarray assay validation = RT-PCR	Testicular tissue (compared with difference in histological pattern) Testicular tissue	NOA = 40 Control = 16	Hsa-miR-34b*, hsa-mir-34b, hsa-mir-34c-5p, hsa-mir-449a, and hsa-mir-449b (hsa-miR-34b*, hsa-miR-34b, hsa-miR-34c-5p, hsa-miR-122) ↓	[39]
Abu-Halima et al. 2014	Germany	NM	RT-PCR	Testicular tissue	NOA = 40 Control = 16	Hsa-miR-34b*, hsa-mir-34b, hsa-mir-34c-5p, hsa-mir-449a, and hsa-mir-449b (hsa-miR-34b*, hsa-miR-34b, hsa-miR-34c-5p, hsa-miR-122) ↓	[40]
Zhou et al. 2019	China	Case = 26.40 ± 3.98 Control = 28.20 ± 3.56 18–41	RT-PCR	Sperm cell	AZ = 30 Control = 30 NOA = 19	Hsa-miR-525-3p ↓	[23]
Tang et al. 2016	China	18–41	RT-PCR	Testicular tissue	NOA = 19 Control (OA) = 6	Hsa-miR-210 ↑	[24]
Zhang et al. 2019	China	Validation group: NOA = 31.000 ± 4.621 Control = 32.531 ± 5.858	Microarray assay validation = RT-PCR	Testicular tissue	NOA = 32 Control = 32	Hsa-miR-10b-3p ↑ Hsa-miR-34b-5p ↓	[25]
Fang et al. 2018	China	22–45	Microarray assay validation = RT-PCR	Testicular tissue	SSR = 5 USR = 5 (All were from NOA patients)	miRNAs related to sperm function in both groups were identified.	[26]
Tang et al. 2018	China	post-cryptorchidopexy NOA = 23, 26, 28 post-cryptorchidopexy OA = 24, 25, 36	Next-generation sequencing (NGS) Validation = RT-PCR	Testicular tissue	Post-cryptorchidopexy NOA = 3 post-cryptorchidopexy OA = 3	152 miRNAs ↑ 297 miRNAs ↓	[27]
Barceló et al. 2018	Spain	21–45	Real-time PCR profiling Validation = RT-qPCR	Semen exosomes	AZ (spermatogenic failure) = 14 OA = 13 Control = 9	hsa-miR-539-5p and hsa-miR-941	[48]
Song et al. 2016	China	NM	RT-PCR	Testicular tissue	AZ = 16 Control = 8	Hsa-miR-188-3p	[28]
Yao et al. 2017	China	25–40	RNA deep sequencing Validation = RT-qPCR	Human spermatogonia, pachytene spermatocytes, round spermatids	OA = 20 NOA = 60	378 microRNAs were differentially expressed in human round spermatids between OA patients and NOA patients	[29]
Mostafá et al. 2016	Egypt	23–39	RT-PCR	Sperm cell	Normozoospermic = 52 Fertile normozoospermic Men with Vx = 43 Infertile OAT men without Vx = 62 Infertile OAT men with Vx = 63 Patient = 38 Control = 30	hsa-miRNA-122, hsa-miRNA-181a, and hsa-miRNA-34c5 were positively correlated with sperm concentration, sperm motility, sperm morphology hsa-miR-371-a-3p is correlated with sperm concentration	[51]
Radtke et al. 2019	Germany	Case: 29.5 (11.5) Control: 36.5 (8.25) Median (IQR) 25.42–33.41	RT-PCR	Seminal plasma	NOA = 96 OS = 96 Control = 96	hsa-miR-19b let-7a ↑	[41]
Wu et al. 2012	China	25.42–33.41	RT-PCR	Seminal plasma	NOA = 96 OS = 96 Control = 96	hsa-miR-19b let-7a ↑	[30]
Boellaard et al. 2019	Netherlands	NM	RT-PCR	Sperm cell	Different samples from urogenital tract N = 9 AZS = 9	hsa-miR-371a-3p related to sperm concentration AS = hsa-miR-34b, hsa-miR-122, hsa-miR-1973	[52]
Abu-Halima et al. 2012	Germany	N = 32.78 ± 5.63 AZS = 34.67 ± 7.87	Microarray assay Validation = RT-PCR	Sperm cell	N = 9 AZS = 9	AS = hsa-miR-34b, hsa-miR-122, hsa-miR-1973	[42]

Table 1 (continued)

Author year	Origin	Age	miRNA measurement technique	Sample type	Studied patients	Identified miRNAs/conclusion	REF
		OA = 31.33 ± 3.94				OA = hsa-miR-34b, hsa-miR-34b*, hsa-miR-15b, hsa-miR-34c-5p, hsa-miR-122, hsa-miR-449a, hsa-miR-1973, hsa-miR-16, and hsa-miR-19a hsa-miR-21, hsa-miR-22 ↑	[46]
Abhari et al. 2014	Iran	27.5 ± 4.8	RT-PCR	Sperm cell	OA = 9 OS = 43 Control = 43	33 DE-hsa-miRNAs	[31]
Li et al. 2016	China	OS = 23–37 OA = 25–28	Microarray assay Validation = RT-PCR	Testicular tissue	OA = 3 OS = 33 Control = 33	hsa-miR-23ab-3p ↑	[43]
Abu-Halima et al. 2019	Germany	20–35	RT-PCR Validation = RT-PCR	Sperm cell	OS = 36 AZ = 36 AS = 36 OSAS = 36	hsa-miR-10a, hsa-miR-10b, hsa-miR-135a, hsa-miR-135b, hsa-miR-888, hsa-miR-891a ↓	[32]
Tian et al. 2017	China	20–45	RT-PCR	Sperm cell	OAS = 12 Control = 12 ASZ = 48 Control = 42	hsa-miR-765 and hsa-miR-1275 ↑ hsa-miR-15a ↓ hsa-miR-27b ↓	[44]
Abu-Halima et al. 2016	Germany	24–39	RT-PCR Validation = RT-PCR	Semen exosomes	AZ = 50 Control = 50	hsa-miR-101-3p, let-7b-5p ↓	[34]
Zhou et al. 2015	China	N = 29.00 ± 4.804 AZS = 30.13 ± 5.841	RT-PCR	Sperm cell	AZ = 73 AZS = 79 OS = 34 Control = 68	sp-miR-151a-5p ↑ AZ = hsa-miR-34c-5p, hsa-miR-122, hsa-miR-146b-5p, hsa-miR-181a, hsa-miR-374b, hsa-miR-509-5p, and hsa-miR-513a-5p ↓	[33]
Zhou et al. 2015	China	NM	RT-PCR	Seminal plasma		AZS = hsa-miR-34c-5p, hsa-miR-122, hsa-miR-146b-5p, hsa-miR-181a, and hsa-miR-513a-5p ↓	[35]
Wang et al. 2011	China	AZ = 29.07 ± 4.67 AZS = 29.41 ± 4.35 OS = 28.82 ± 5.31 Control = 28.63 ± 4.40	RT-PCR	Seminal plasma		hsa-miR-374b, hsa-miR-509-5p, and hsa-miR-513a-5p ↑	[36]
Qing et al. 2017	China	AZS = 33.73 ± 6.63 N = 33.00 ± 7.22	RT-PCR	Seminal plasma	AZS = 22 N = 22	hsa-miR-891b, hsa-miR-892b, hsa-miR-892a, hsa-miR-888, hsa-miR-890	[37]
Zhou et al. 2018	China	NM	TaqMan low-density array Validation = RT-PCR	Seminal plasma	AZS = 50 N = 50	let-7b-5p ↓	[47]
Heidary et al. 2018	Iran	AZS = 36.7 ± 6.87 Control = 35.7 ± 5.05	Illumina high-throughput sequencing Validation = RT-PCR	Sperm cell	AS = 39 Control = 35	Hsa-miR-888-3p ↑	[53]
Salas-Huetos et al. 2014	Spain	NM	TaqMan array	Sperm cell	10 males with normal seminogram	None of the miRNAs correlated with sperm motility, morphology or concentration	[38]
Zhou et al. 2017	China	AZS = 33.30 ± 1.46 Control = 29.60 ± 1.05	RT-PCR	Sperm cell	AZS = 20 Control = 20	hsa-miR-27a ↑	[49]
Salas-Huetos et al. 2015	Spain	19–50	RT-PCR	Sperm cell	AZS = 10 TS = 10 OS = 10 AZS = 10 TS = 10 OS = 10	AZS = 32 DE-miRNAs TS = 19 DE-miRNAs OS = 18 DE-miRNAs	[50]
Corral-Vazquez et al. 2019	Spain	NM	RT-PCR	Sperm cell		AZS = hsa-miR-942-5p/hsa-miR-1208 TS = hsa-miR-296-5p/hsa-miR-328-3p OS = hsa-miR-139-5p/hsa-miR-1260a	[50]

Fig. 2 Study flowchart



compared to normal samples. Functional classification of the miRNA/mRNA pairs using bioinformatics tools indicated that the genes with different expression patterns play a role in spermatogenesis, cell meiosis, cell cycle, and development of secondary male sexual charac *hsa-miR-210* has been shown to be upregulated in NOA patients which target insulin-like growth factor II (IGF2) [24]. Using microarray technology, Zhang et al. identified 129 miRNAs with different expression levels in testicular tissue samples of NOA patients which were involved in spermatogenesis, cell cycle, and mitotic prometaphase [25]. Microdissection testicular sperm extraction (micro-TESE) is used for NOA patients in order to retrieve sperm cells to be used in intracytoplasmic sperm injection (ICSI). Fang et al. 2018 evaluated the level of miRNAs in testicular tissue samples including successfully retrieved sperm (SRS) and unsuccessfully retrieved sperm (URS) as a new biomarker before micro-TESE. They identified different expression levels of miRNAs between SRS and URS groups which participate in important cellular processes related to spermatogenesis [26]. MiRNAs play a vital role in cryptorchidism in addition to the reproductive disorders mentioned above [27]. Attempts to find miRNAs inside small extracellular vesicles as a non-invasive diagnostic tool revealed different expression patterns of multiple miRNAs with two miRNAs, *hsa-miR-539-5p* and *hsa-miR-941*, promising to be useful markers for predicting the presence of spermatozoa in

azoospermic patients before testicular biopsy [48]. Further studies in order to reveal the role of miRNAs in sperm cells of azoospermic patients identified downregulation of *hsa-miR-188-3p* resulting in upregulation of *MLH1* and induction of apoptosis in spermatozoa [28]. The expression level of miRNAs in human spermatogonia, pachytene spermatocytes, and round spermatids between NOA and OA patients showed differences between mentioned groups and concluded that miRNA mimics and miRNA inhibitors could be used in order to down- and upregulate miRNAs respectively in order to restore normal spermatogenesis in AZ patients [29].

Oligospermia

Oligospermia (OS) is defined as sperm cell count lower than 15 million/ml in male ejaculate [58]. OS is usually associated with defects in sperm motility and morphology [59]. This categorization based on sperm density has limited diagnostic value because no threshold value has been defined, for instance, 5% of the fertile male are OS or even men with 1–5 million sperm count can have natural conception [60]. Deletions in the Y chromosome and karyotype anomalies have been reported in oligospermic patients, but still, further research is required in order to reach a better understanding of molecular elements playing role in OS [61].




Fig. 3 Predicted miRNAs A: AZ, B: OS, C: AZS, D: TS

Expression of *hsa-miR-122*, *hsa-miR-181a*, and *hsa-miR-34c5* is positively correlated with sperm concentration, motility, and morphology [51]. Also, the expression of *hsa-miR-371a-3p* in seminal plasma is correlated with sperm concentration [41]. *hsa-miR-19b* and *let-7a* are reported to have a higher expression level in NOA patients, but no significant difference was observed in OS patients [30]. The analysis on expression level of *miR-371a-3p* on different urogenital tract tissues indicated that only testis parenchyma and semen samples had detectable expression levels of this miRNAs and moreover, its expression is correlated with sperm concentration [52]. Study of miRNA expression levels using microarrays show upregulation of 50 miRNAs and

downregulation of 27 miRNAs in asthenozoospermic males, and also upregulation of 42 miRNAs and downregulation of 44 miRNAs in oligoasthenozoospermic men. Further bioinformatic analysis also indicated that these miRNAs regulate important genes which play a role in spermatogenesis, apoptosis, sperm chromatin compaction, and sperm motility [42]. Estrogen plays an important role in sperm capacitation and fertilization potential and since increased expression levels of *hsa-mir-21* and *hsa-mir-22* have been associated with lower expression of estrogen receptor beta in oligospermic patients, miRNAs have been indicated to have a regulatory role in male infertility [46]. Another study on the expression levels of miRNAs and mRNAs on testicular




Fig. 4 Kegg pathways A: AZ, B: OS, C: AZS, D: TS

tissue samples of severe oligospermia and obstructive azoospermia indicated differential expression of mRNAs and miRNAs. One such miRNA-mRNA pair, namely *hsa-miR-34c-3p* and *PLCXD3* (phosphatidylinositol-specific phospholipase C, X domain containing 3), is of special interest since *hsa-miR-34c-3p* expression in mouse and human cell lines reduced *PLCXD3* levels which is known to regulate cytosolic calcium levels important for male fertility [31]. A study on oligoasthenospermic patients indicated that the expression of *miR-23a/b-3p* is negatively correlated with sperm motility, morphology, and sperm count and some of its identified direct targets including *PFKFB4*, *HMMR*, *SPATA6*, and *TEX15* have fundamental role in sperm function [43]. Another Chinese study has evaluated the expression level of six miRNAs (*hsa-miR-10a*, *hsa-miR-10b*, *hsa-miR-135a*, *hsa-miR-135b*, *hsa-miR-888*, and *hsa-miR-891a*), in different infertile male groups including asthenozoospermia, OS, azoospermia, OS, and asthenozoospermia (OSAS) and reported lower expression levels of the abovementioned miRNAs in all infertile groups compared to fertile men [32]. Moreover, studies about semen or testicular tissue samples and extracellular microvesicle miRNA levels in the seminal plasma of patients with oligoasthenozoospermia have been published reporting 7 upregulated and 29 downregulated miRNAs in oligoasthenozoospermic cases and suggested that these miRNAs participate in spermatogenesis or its related processes [44].

Asthenozoospermia

Males harboring sperm motility defects such as reduced progressive motility or lack of motility are considered to have asthenozoospermia (AZS) [58]. AZS is responsible for almost 20% of

male infertility cases and in 60% of the cases AZS is accompanied by OS (oligoasthenozoospermia) or teratozoospermia (oligoasthenoteratozoospermia, asthenoteratozoospermia) [62]. Multiple genetic factors are involved in AZS etiology including chromosomal aberrations, mutations in genes involved in sperm motility, mitochondrial DNA mutations, epigenetic aberration, and miRNAs [63].

Various studies have attempted to show the role of miRNAs in sperm motility defects. *CRISP2* (cysteine-rich secretory protein 2) regulates calcium influx through ryanodine receptors and is located in sperm acrosome and tail. Studies on AZS semen samples have shown lower expression of *CRISP2* and higher expression of *hsa-miR-27b* and have indicated the regulatory role of this gene-miRNA pair in sperm motility [33]. Studies on seminal miRNAs in AZS patients showed higher expression of *hsa-miR-151a-5p* and lower expression of *hsa-miR-101-3p* and *let-7b-5p* compared to control samples. Transfecting GC-2 cells with *hsa-miR-151a-5p* mimics resulted in decreased levels of adenosine triphosphate (ATP) and cytochrome b (Cytb) protein and mRNA [34]. Interestingly, study of Wang et al. identified 7 miRNAs (*hsa-miR-34c-5p*, *hsa-miR-122*, *hsa-miR-146b-5p*, *hsa-miR-181a*, *hsa-miR-374b*, *hsa-miR-509-5p*, and *hsa-miR-513a-5p*) which was upregulated in AZS patients but downregulated in AZ patients [35]. Expression of five miRNAs (*hsa-miR-891b*, *hsa-miR-892b*, *hsa-miR-892a*, *hsa-miR-888*, and *hsa-miR-890*) was dysregulated in ASZ patients which were correlated to sperm motility. Bioinformatics analysis identified these miRNAs to be important in regulating sperm motility-related pathways [36]. Zhou et al. (2018) showed lower expression of *let-7b-5p* in sever ASZ compared to control. They also indicated that *let-7b-5p* acts in glycolysis metabolism by targeting aurora kinase B (AURKB) [37]. High-throughput




Fig. 5 GO terms A: AZ, B: OS, C: AZS, D: TS. (blue: biological process, red: molecular function, green: cellular component)

sequencing on the sperm samples of idiopathic AZS patients revealed 18 miRNAs with altered expression levels which via validation with real-time PCR showed *hsa-miR-888-3p* to be highly upregulated compared to controls [47].

Teratozoospermia

Teratozoospermia (TS) is defined as having more than 85% morphologically abnormal sperm cell in ejaculate [64]. TS is divided into two subtypes, monomorphic and polymorphic. In monomorphic TS, all sperm cells harbor the same morphological abnormality while in polymorphic type, there are different kinds of morphological abnormalities [65]. Monomorphic type of TS is divided into two main categories: macrozoospermia (sperm cells with large misshaped heads) and globozoospermia (sperm cells with an oval-shaped head) [66]. Studies have demonstrated that various genetic factors play a role in morphologically abnormal sperm cells including aneuploidy, sperm DNA fragmentation, and mutations [67]. One of these genetic factors, as mentioned above, are miRNAs involved in morphogenesis.

Salas-Huetos et al. (2014) studied 736 miRNAs in human spermatozoa but reported no correlation between any of these miRNAs and sperm concentration, motility, and morphology [53]. Study on asthenoteratozoospermic semen samples indicated that the upregulation of *hsa-miR-27a* results in lower levels of cysteine-rich secretory protein 2 (*CRISP2*), an important protein for sperm motility [38]. Two studies by using TaqMan quantitative polymerase chain reaction (PCR) identified multiple miRNAs in different sperm characteristics defects, including teratozoospermia. Salas-Huetos et al. identified 32 miRNAs in AZS, 19 miRNAs in TS, and 18 miRNAs in OS group with altered expression which ontological

analysis showed these miRNAs may have role in proper sperm cell function [49]. Corral-Vazquez et al. reported that *hsa-miR-942-5p/hsa-miR-1208* in asthenozoospermia, *hsa-miR-296-5p/hsa-miR-328-3p* in teratozoospermia, and *hsa-miR-139-5p/hsa-miR-1260a* in oligozoospermia had altered expression compared to control samples [50]

In silico prediction of miRNAs in AZ, OS, AS, and TS

The DisGeNET database reported 173 genes associated with AZ (Supplementary Table 2). Based on these genes, we reached seven predicted miRNAs with the highest number of targeting genes (Supplementary Table 3). Between these miRNAs, *hsa-miR-548c-3p* had the greatest number of target genes (65 genes). The only reported involvement of this miRNA in human diseases has been in human alcoholic cardiomyopathy [68]. Interactions between this miRNA and its targeted genes are shown in Fig. 3 a.

The DisGeNET database reports 108 genes associated with OS (Supplementary Table 2) and after further bioinformatics analysis, 9 miRNAs with the highest number of targeted genes were selected for further analysis (Supplementary Table 4). Between miRNAs with the highest number of targets, *hsa-miR-3163* and *hsa-miR-548c-3p* had the greatest number of target genes. *hsa-miR-548c-3p* is shared with the AZS group. *hsa-miR-3163* has been reported to be involved in non-small-cell lung cancer cell growth by suppressing the translation of *Skp2* to inhibit NSCLC cell growth [69]. The interaction network of the abovementioned miRNAs and their target genes is shown in Fig. 3 b.

The DisGeNET database reports 34 genes associated with AZS (Supplementary Table 2) and further bioinformatic

analysis revealed 67 miRNAs with the highest number of targets (Supplementary Table 5). *hsa-miR-671-5p* had the most target genes among predicted miRNAs in AZS (11 genes). This miRNA has been reported to participate in various cancers including hepatocellular carcinoma, pediatric chordomas, soft tissue sarcomas, glioblastoma multiforme, breast cancer, and epithelioid sarcoma [70–75]. The interaction network of *hsa-miR-671-5p* and its target genes is shown in Fig. 3 c.

The DisGeNET database reported 18 genes associated with TS (Supplementary Table 2) and 100 miRNAs were chosen between miRNAs with the highest number of targets for further analysis (Supplementary Table 6). Three miRNAs including *hsa-miR-203a*, *hsa-miR-340-5p*, and *hsa-miR-3613-3p* had the most target genes. Previous studies have reported these miRNAs to be important in various types of diseases including rheumatic carditis [76], nasopharyngeal carcinoma [77], influenza A [78], Parkinson's disease [79], and hepatocellular carcinoma [80]. MiRNA-gene interaction network of the abovementioned miRNAs is shown in Fig. 3 d.

Pathways and GO terms

KEGG enrichment analysis of genes and predicted miRNAs involved in AZ results in eight pathways including gap junction, glycosaminoglycan biosynthesis, chondroitin sulfate/dermatan sulfate, apoptosis, proteoglycans in cancer, mismatch repair, miRNAs in cancer, estrogen signaling pathway, and arrhythmogenic right ventricular cardiomyopathy (ARVC) (Fig. 4 a). The most significantly enriched terms on BP, CC, and MF are listed in Fig. 5 a. Most BP terms are involved in sperm cell generation including spermatogenesis, synaptonemal complex assembly, male meiosis, and positive regulation of male gonad development.

In OS group, KEGG enrichment analysis resulted in five pathways including hematopoietic cell lineage, mismatch repair, prostate cancer, cysteine, and methionine metabolism and graft-versus-host disease (Fig. 4 b). Also, GO enrichment analysis results including BP, MF, and CC terms are depicted in Fig. 5 b.

In AZS group, the first 30 KEGG enrichment results are summarized in Fig. 4 c. The first four pathways are related to sperm motility based on p value score ($p < 0.05$). Also, multiple pathways are related to calcium and chloride ion transportation which have both been shown to have a fundamental role in sperm motility and male fertility [81, 82]. Similar to KEGG enrichment results, most of the GO enrichment terms are related to sperm motility which indicates predicted miRNAs and their target genes may have important roles in sperm mobility (Fig. 5 c).

In the TS group, KEGG enrichment analysis resulted in four pathways including cell adhesion molecules (CAMs),

inflammatory bowel disease (IBD), mismatch repair, and hepatitis B (Fig. 4 d). GO enrichment analysis results are summarized in Fig. 5 d which mostly emphasize spermatogenesis.

Conclusion

Despite numerous efforts to find responsible underlying factors for male infertility, a great proportion of these patients are still reported as unexplained infertility. MiRNAs have been reported as novel biomarkers that can clarify ambiguities about male infertility [31]. Spermatogenesis is regulated by almost 1500 to 2000 genes and genetic alteration of these genes and also their regulatory molecules including miRNAs are emerging research topics for infertility [83, 84]. Understating of responsible molecular changes in infertility is in the utmost importance to find new therapeutic ways and avoid time-consuming and painful treatments [67]. In the current study, we have systematically reviewed the potential role of miRNAs in infertile male with azoospermia, asthenozoospermia, teratozoospermia, and oligospermia. Using different samples, different patient characteristics and inclusion criteria result in high heterogeneity between the included studies, so we were unable to conduct meta-analysis in order to find exact correlation between miRNAs and sperm characteristics. We have also used bioinformatics tools to predict novel miRNAs in each group and their role in biological processes and pathways.

Between the identified pathways, mismatch repair was in common between all groups. Sperm cells undergo multiple stages of mitosis and meiosis cycles and DNA repair is essential for maintaining the genomic integrity of the sperm. Defects in components of this system have been reported both in infertile males and in animal models [85]. Predicted miRNAs in this study are involved in regulating this important system, and thus further studies on these miRNAs and their target genes may help clarify new aspects in male infertility.

A number of previously validated miRNAs in male infertility, discussed in previous sections of this review, are among the miRNAs predicted by our pipeline. These include, *hsa-mir-141* [22], *hsa-miR-34b* [40], *hsa-miR-34c-5p* [40], *hsa-miR-122* [40], *hsa-miR-429* [40], *hsa-miR-942* [48] among the AZ group, *Let-7a* [30], *hsa-miR-21* [46], *hsa-miR-22* [46], *hsa-miR-34c-3p* [31], *hsa-miR-135a* [32], *hsa-miR-135b* [32], *hsa-miR-888* [32] among OS group and *let-7b-5p* [34], *hsa-miR-891b* [36], *hsa-miR-892b* [36], *hsa-miR-892a* [36], *hsa-miR-888* [36], *hsa-miR-890* [66] among the AZS group. This helps show the potential of using our pipeline for future experimental studies. Using bioinformatics tools, novel miRNAs have been predicted in different infertile groups of patients including AZ (*hsa-miR-548c-3p*), OS (*hsa-miR-3163*, *hsa-miR-548c-3p*), AZS (*hsa-miR-671-5p*), and teratozoospermia (*hsa-miR-203a*, *hsa-miR-340-5p*, *hsa-miR-3613-3p*). Predicted miRNAs of this study are involved in major pathways and GO terms related to sperm function. Regarding the high rate of false-positive results in target prediction algorithms,

still more studies are required to validate identified miRNAs [86]. Also, these miRNAs can be further studied experimentally to be used as novel possible biomarkers for infertile male.

Acknowledgments This article is the result of a student dissertation approved by Tabriz University of Medical Sciences code 59077. We also want to thank the Stem Cell Research Center of Tabriz University of Medical Sciences for their collaboration.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

References

- World Health Organization %J WHO G. Report of the meeting on the prevention of infertility at the primary health care level. 1983:12–6.
- Hamada A, Esteves SC, Agarwal A. Unexplained male infertility: potential causes and management. *Hum Androl*. 2011;1(1):2–16. <https://doi.org/10.1097/01.Xha.0000397686.82729.09>.
- Hargreave TB. Genetic basis of male fertility. *Br Med Bull*. 2000;56(3):650–71.
- Hamada A, Esteves SC, Nizza M, Agarwal A. Unexplained male infertility: diagnosis and management. *Int Braz J Urol*. 2012;38(5):576–94.
- Neto FT, Bach PV, Najari BB, Li PS, Goldstein M. Spermatogenesis in humans and its affecting factors. *Semin Cell Dev Biol*. 2016;59:10–26. <https://doi.org/10.1016/j.semedb.2016.04.009>.
- Mukherjee A, Koli S, Reddy KV. Regulatory non-coding transcripts in spermatogenesis: shedding light on 'dark matter'. *Andrology*. 2014;2(3):360–9. <https://doi.org/10.1111/j.2047-2927.2014.00183.x>.
- Le Bot N. miRNAs and cell-cycle control in ESCs. *Nat Cell Biol*. 2012;14:658. <https://doi.org/10.1038/ncb2544>.
- Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. *Nucleic Acids Res*. 2005;33(4):1290–7. <https://doi.org/10.1093/nar/gki200>.
- Tahmasbpour E, Balasubramanian D, Agarwal A. A multi-faceted approach to understanding male infertility: gene mutations, molecular defects and assisted reproductive techniques (ART). *J Assist Reprod Genet*. 2014;31(9):1115–37. <https://doi.org/10.1007/s10815-014-0280-6>.
- Harchegani AB, Shafaghathian H, Tahmasbpour E, Shahriari A. Regulatory functions of microRNAs in male reproductive health: a new approach to understanding male infertility. *Reprod Sci*. 2018;1933719118765972. <https://doi.org/10.1177/1933719118765972>.
- Chen X, Li X, Guo J, Zhang P, Zeng W. The roles of microRNAs in regulation of mammalian spermatogenesis. *J Anim Sci Biotechnol*. 2017;8:35. <https://doi.org/10.1186/s40104-017-0166-4>.
- Tesfaye D, Salilew-Wondim D, Gebremedhn S, Sohel MM, Pandey HO, Hoelker M, et al. Potential role of microRNAs in mammalian female fertility. *Reprod Fertil Dev*. 2016;29(1):8–23. <https://doi.org/10.1071/rd16266>.
- Ostermeier GC, Goodrich RJ, Moldenhauer JS, Diamond MP, Krawetz SA. A suite of novel human spermatozoal RNAs. *J Androl*. 2005;26(1):70–4.
- Khazaie Y, Nasr Esfahani MH. MicroRNA and male infertility: a potential for diagnosis. *Int J Fertil Steril*. 2014;8(2):113–8.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097. <https://doi.org/10.1371/journal.pmed.1000097>.
- Piñero J, Bravo À, Queralt-Rosinach N, Gutiérrez-Sacristán A, Deu-Pons J, Centeno E, et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. *Nucleic Acids Res*. 2016;45(D1):D833–D9. <https://doi.org/10.1093/nar/gkw943>.
- Sticht C, De La Torre C, Parveen A, Gretz N. miRWalk: an online resource for prediction of microRNA binding sites. *PLOS ONE*. 2018;13(10):e0206239. <https://doi.org/10.1371/journal.pone.0206239>.
- Afgan E, Baker D, Batut B, van den Beek M, Bouvier D, Cech M, et al. The galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. *Nucleic Acids Res*. 2018;46(W1):W537–w44. <https://doi.org/10.1093/nar/gky379>.
- Vlachos IS, Zagganas K, Paraskevopoulou MD, Georgakilas G, Karagkouni D, Vergoulis T, et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. *Nucleic Acids Res*. 2015;43(W1):W460–W6. <https://doi.org/10.1093/nar/gkv403>.
- Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res*. 2003;13(11):2498–504. <https://doi.org/10.1101/gr.1239303>.
- Lian J, Zhang X, Tian H, Liang N, Wang Y, Liang C, et al. Altered microRNA expression in patients with non-obstructive azoospermia. *Reprod Biol Endocrinol*. 2009;7(1):13. <https://doi.org/10.1186/1477-7827-7-13>.
- Wu W, Qin Y, Li Z, Dong J, Dai J, Lu C, et al. Genome-wide microRNA expression profiling in idiopathic non-obstructive azoospermia: significant up-regulation of miR-141, miR-429 and miR-7-1-3p. *Hum Reprod*. 2013;28(7):1827–36. <https://doi.org/10.1093/humrep/det099>.
- Zhou QZ, Guo XB, Zhang WS, Zhou JH, Yang C, Bian J, et al. Expressions of miR-525-3p and its target gene SEMG1 in the spermatozoa of patients with asthenozoospermia. *Andrology*. 2019;7(2):220–7. <https://doi.org/10.1111/andr.12573>.
- Tang D, Huang Y, Liu W, Zhang X. Up-regulation of microRNA-210 is associated with spermatogenesis by targeting IGF2 in male infertility. *Med Sci Monit*. 2016;22:2905–10. <https://doi.org/10.12659/msm.897340>.
- Zhang HT, Zhang Z, Hong K, Tang WH, Liu DF, Mao JM, et al. Altered microRNA profiles of testicular biopsies from patients with nonobstructive azoospermia. *Asian J Androl*. 2019. https://doi.org/10.4103/aja.aja_35_19.
- Fang N, Cao C, Wen Y, Wang X, Yuan S, Huang X. MicroRNA profile comparison of testicular tissues derived from successful and unsuccessful microdissection testicular sperm extraction retrieval in non-obstructive azoospermia patients. *Reprod Fertil Dev*. 2018. <https://doi.org/10.1071/rd17423>.
- Tang D, Huang Z, He X, Wu H, Peng D, Zhang L, et al. Altered miRNA profile in testis of post-cryptorchidopexy patients with non-obstructive azoospermia. *Reprod Biol Endocrinol*. 2018;16(1):78. <https://doi.org/10.1186/s12958-018-0393-3>.
- Song WY, Meng H, Wang XG, Jin HX, Yao GD, Shi SL, et al. Reduced microRNA-188-3p expression contributes to apoptosis of spermatogenic cells in patients with azoospermia. *Cell Prolif*. 2017;50(1). <https://doi.org/10.1111/cpr.12297>.
- Yao C, Yuan Q, Niu M, Fu H, Zhou F, Zhang W, et al. Distinct expression profiles and novel targets of microRNAs in human spermatogonia, Pachytene spermatocytes, and round spermatids between OA patients and NOA patients. *Mol Ther Nucleic Acids*. 2017;9:182–94. <https://doi.org/10.1016/j.omtn.2017.09.007>.
- Wu W, Hu Z, Qin Y, Dong J, Dai J, Lu C, et al. Seminal plasma microRNAs: potential biomarkers for spermatogenesis status. *Mol Hum Reprod*. 2012;18(10):489–97. <https://doi.org/10.1093/molehr/gas022>.

31. Li Z, Zheng Z, Ruan J, Li Z, Zhuang X, Tzeng C-M. Integrated analysis miRNA and mRNA profiling in patients with severe oligozoospermia reveals miR-34c-3p downregulates PLCXD3 expression. *Oncotarget*. 2016;7(33):52781–96. <https://doi.org/10.18632/oncotarget.10947>.
32. Tian H, Lv M, Li Z, Peng D, Tan Y, Wang H, et al. Semen-specific miRNAs: suitable for the distinction of infertile semen in the body fluid identification? *Forensic Sci Int Genet*. 2018;33:161–7. <https://doi.org/10.1016/j.fsigen.2017.12.010>.
33. Zhou JH, Zhou QZ, Lyu XM, Zhu T, Chen ZJ, Chen MK, et al. The expression of cysteine-rich secretory protein 2 (CRISP2) and its specific regulator miR-27b in the spermatozoa of patients with asthenozoospermia. *Biol Reprod*. 2015;92(1):28. <https://doi.org/10.1095/biolreprod.114.124487>.
34. Zhou R, Wang R, Qin Y, Ji J, Xu M, Wu W, et al. Mitochondria-related miR-151a-5p reduces cellular ATP production by targeting CYTB in asthenozoospermia. *Sci Rep*. 2015;5:17743. <https://doi.org/10.1038/srep17743>.
35. Wang C, Yang C, Chen X, Yao B, Yang C, Zhu C, et al. Altered profile of seminal plasma microRNAs in the molecular diagnosis of male infertility. *Clin Chem*. 2011;57(12):1722–31. <https://doi.org/10.1373/clinchem.2011.169714>.
36. Qing X, Shi J, Dong T, Wu C, Hu L, Li H. Dysregulation of an X-linked primate-specific epididymal microRNA cluster in unexplained asthenozoospermia. *Oncotarget*. 2017;8(34):56839–49. <https://doi.org/10.18632/oncotarget.18076>.
37. Zhou R, Zhang Y, Du G, Han L, Zheng S, Liang J, et al. Down-regulated let-7b-5p represses glycolysis metabolism by targeting AURKB in asthenozoospermia. *Gene*. 2018;663:83–7. <https://doi.org/10.1016/j.gene.2018.04.022>.
38. Zhou JH, Zhou QZ, Yang JK, Lyu XM, Bian J, Guo WB, et al. MicroRNA-27a-mediated repression of cysteine-rich secretory protein 2 translation in asthenozoospermic patients. *Asian J Androl*. 2017;19(5):591–5. <https://doi.org/10.4103/1008-682x.185001>.
39. Abu-Halima M, Backes C, Leidinger P, Keller A, Lubbad AM, Hammadeh M, et al. MicroRNA expression profiles in human testicular tissues of infertile men with different histopathologic patterns. *Fertil Steril*. 2014;101(1):78–86.e2. <https://doi.org/10.1016/j.fertnstert.2013.09.009>.
40. Abu-Halima M, Hammadeh M, Backes C, Fischer U, Leidinger P, Lubbad AM, et al. Panel of five microRNAs as potential biomarkers for the diagnosis and assessment of male infertility. *Fertil Steril*. 2014;102(4):989–97.e1. <https://doi.org/10.1016/j.fertnstert.2014.07.001>.
41. Radtke A, Dieckmann KP, Grobelny F, Salzbrunn A, Oing C, Schulze W, et al. Expression of miRNA-371a-3p in seminal plasma and ejaculate is associated with sperm concentration. *Andrology*. 2019;7(4):469–74. <https://doi.org/10.1111/andr.12664>.
42. Abu-Halima M, Hammadeh M, Schmitt J, Leidinger P, Keller A, Meese E, et al. Altered microRNA expression profiles of human spermatozoa in patients with different spermatogenic impairments. *Fertil Steril*. 2013;99(5):1249–55.e16. <https://doi.org/10.1016/j.fertnstert.2012.11.054>.
43. Abu-Halima M, Ayesh BM, Hart M, Alles J, Fischer U, Hammadeh M, et al. Differential expression of miR-23a/b-3p and its target genes in male patients with subfertility. *Fertil Steril*. 2019;112(2):323–35.e2. <https://doi.org/10.1016/j.fertnstert.2019.03.025>.
44. Abu-Halima M, Ludwig N, Hart M, Leidinger P, Backes C, Keller A, et al. Altered micro-ribonucleic acid expression profiles of extracellular microvesicles in the seminal plasma of patients with oligoasthenozoospermia. *Fertil Steril*. 2016;106(5):1061–9.e3. <https://doi.org/10.1016/j.fertnstert.2016.06.030>.
45. Mashizy SKSM, Mokhtari M, Khatamsaz S. The relationship between expression of Mir30 and Let7 genes in infertile males and non-obstructive azoospermia. *Biosci EJ*. 2019;13(1).
46. Abhari A, Zarghami N, Farzadi L, Nouri M, Shahnaazi V. Altered of microRNA expression level in oligospermic patients. *Iran J Reprod Med*. 2014;12(10):681–6.
47. Heidary Z, Zaki-Dizaji M, Saliminejad K, Khorram Khorshid HR. MicroRNA profiling in spermatozoa of men with unexplained asthenozoospermia. *Andrologia*. 2019;51(6):e13284. <https://doi.org/10.1111/and.13284>.
48. Barcelo M, Mata A, Bassas L, Larriba S. Exosomal microRNAs in seminal plasma are markers of the origin of azoospermia and can predict the presence of sperm in testicular tissue. *Hum Reprod*. 2018;33(6):1087–98. <https://doi.org/10.1093/humrep/dey072>.
49. Salas-Huetos A, Blanco J, Vidal F, Godo A, Grossmann M, Pons MC, et al. Spermatozoa from patients with seminal alterations exhibit a differential micro-ribonucleic acid profile. *Fertil Steril*. 2015;104(3):591–601. <https://doi.org/10.1016/j.fertnstert.2015.06.015>.
50. Corral-Vazquez C, Salas-Huetos A, Blanco J, Vidal F, Sarrate Z, Anton E. Sperm microRNA pairs: new perspectives in the search for male fertility biomarkers. *Fertil Steril*. 2019. <https://doi.org/10.1016/j.fertnstert.2019.07.006>.
51. Mostafa T, Rashed LA, Nabil NI, Osman I, Mostafa R, Farag M. Seminal miRNA relationship with apoptotic markers and oxidative stress in infertile men with varicocele. *Biomed Res Int*. 2016;2016:4302754. <https://doi.org/10.1155/2016/4302754>.
52. Boellaard WPA, Gillis AJM, van Leenders G, Stoop H, van Agthoven T, Dorssers LCJ, et al. Cellular origin of microRNA-371a-3p in healthy males based on systematic urogenital tract tissue evaluation. *Andrology*. 2019;7(4):463–8. <https://doi.org/10.1111/andr.12595>.
53. Salas-Huetos A, Blanco J, Vidal F, Mercader JM, Garrido N, Anton E. New insights into the expression profile and function of micro-ribonucleic acid in human spermatozoa. *Fertil Steril*. 2014;102(1):213–22.e4. <https://doi.org/10.1016/j.fertnstert.2014.03.040>.
54. Anderson JE, Farr SL, Jamieson DJ, Warner L, Macaluso M. Infertility services reported by men in the United States: national survey data. *Fertil Steril*. 2009;91(6):2466–70. <https://doi.org/10.1016/j.fertnstert.2008.03.022>.
55. Huang IS, Huang WJ, Lin AT. Distinguishing non-obstructive azoospermia from obstructive azoospermia in Taiwanese patients by hormone profile and testis size. *J Chin Med Assoc*. 2018;81(6):531–5. <https://doi.org/10.1016/j.jcma.2017.09.009>.
56. Hernandez Uribe L, Hernandez Marin I, Cervera-Aguilar R, Ayala AR. Frequency and etiology of azoospermia in the study of infertile couples. *Ginecol Obstet Mex*. 2001;69:322–6.
57. Hamada AJ, Esteves SC, Agarwal A. A comprehensive review of genetics and genetic testing in azoospermia. *Clinics (Sao Paulo)*. 2013;68(Suppl 1):39–60.
58. World Health Organization. World Health Organization laboratory manual for the evaluation and processing of human semen. 5th ed. Cambridge: Cambridge University Press; 2010.
59. Liu DY, Baker HW. Defective sperm-zona pellucida interaction: a major cause of failure of fertilization in clinical in-vitro fertilization. *Hum Reprod*. 2000;15(3):702–8.
60. McLachlan RI. Approach to the patient with oligozoospermia. *J Clin Endocrinol Metab*. 2013;98(3):873–80. <https://doi.org/10.1210/jc.2012-3650>.
61. McLachlan RI, O'Bryan MK. Clinical review#: state of the art for genetic testing of infertile men. *J Clin Endocrinol Metab*. 2010;95(3):1013–24. <https://doi.org/10.1210/jc.2009-1925>.
62. Asero P, Calogero AE, Condorelli RA, Mongioi L, Vicari E, Lanzafame F, et al. Relevance of genetic investigation in male infertility. *J Endocrinol Investig*. 2014;37(5):415–27. <https://doi.org/10.1007/s40618-014-0053-1>.
63. Heidary Z, Saliminejad K, Zaki-Dizaji M, Khorram Khorshid HR. Genetic aspects of idiopathic asthenozoospermia as a cause of male infertility. *Hum Fertil (Camb)*. 2018;1–10. <https://doi.org/10.1080/14647273.2018.1504325>.

64. Perrin A, Huong Nguyen M, Douet-Guilbert N, Morel F, De Braekeleer M. Motile sperm organelle morphology examination: where do we stand 12 years later? 2014.
65. Perrin A, Morel F, Moy L, Collet D, Amice V, De Braekeleer M. Study of aneuploidy in large-headed, multiple-tailed spermatozoa: case report and review of the literature. *Fertil Steril*. 2008;90(4):1201.e13–7. <https://doi.org/10.1016/j.fertnstert.2007.09.013>.
66. Perrin A, Coat C, Nguyen MH, Talagas M, Morel F, Amice J, et al. Molecular cytogenetic and genetic aspects of globozoospermia: a review. *Andrologia*. 2013;45(1):1–9. <https://doi.org/10.1111/j.1439-0272.2012.01308.x>.
67. De Braekeleer M, Nguyen MH, Morel F, Perrin A. Genetic aspects of monomorphic teratozoospermia: a review. *J Assist Reprod Genet*. 2015;32(4):615–23. <https://doi.org/10.1007/s10815-015-0433-2>.
68. Jing L, Jin C, Lu Y, Huo P, Zhou L, Wang Y, et al. Investigation of microRNA expression profiles associated with human alcoholic cardiomyopathy. *Cardiology*. 2015;130(4):223–33. <https://doi.org/10.1159/000370028>.
69. Su L, Han D, Wu J, Huo X. Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163. *Tumour Biol*. 2016;37(3):3925–31. <https://doi.org/10.1007/s13277-015-4151-2>.
70. Dou C, Zhou Z, Xu Q, Liu Z, Zeng Y, Wang Y, et al. Hypoxia-induced TUFT1 promotes the growth and metastasis of hepatocellular carcinoma by activating the Ca(2+)/PI3K/AKT pathway. *Oncogene*. 2019;38(8):1239–55. <https://doi.org/10.1038/s41388-018-0505-8>.
71. Malgulwar PB, Pathak P, Singh M, Kale SS, Suri V, Sarkar C, et al. Downregulation of SMARCB1/INI1 expression in pediatric chordomas correlates with upregulation of miR-671-5p and miR-193a-5p expressions. *Brain Tumor Pathol*. 2017;34(4):155–9. <https://doi.org/10.1007/s10014-017-0295-7>.
72. Sapi Z, Papp G, Szendroi M, Papai Z, Plotar V, Krausz T, et al. Epigenetic regulation of SMARCB1 by miR-206, -381 and -671-5p is evident in a variety of SMARCB1 immunonegative soft tissue sarcomas, while miR-765 appears specific for epithelioid sarcoma. A miRNA study of 223 soft tissue sarcomas. *Genes Chromosome Cancer*. 2016;55(10):786–802. <https://doi.org/10.1002/gcc.22379>.
73. Barbagallo D, Condorelli A, Ragusa M, Salito L, Sammito M, Banelli B, et al. Dysregulated miR-671-5p / CDR1-AS / CDR1 / VSNL1 axis is involved in glioblastoma multiforme. *Oncotarget*. 2016;7(4):4746–59. <https://doi.org/10.18632/oncotarget.6621>.
74. Tan X, Fu Y, Chen L, Lee W, Lai Y, Rezaei K, et al. miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer. *Oncotarget*. 2016;7(1):293–307. <https://doi.org/10.18632/oncotarget.6344>.
75. Papp G, Krausz T, Stricker TP, Szendroi M, Sapi Z. SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on both mRNA and protein levels. *Genes Chromosome Cancer*. 2014;53(2):168–76. <https://doi.org/10.1002/gcc.22128>.
76. Gumus G, Giray D, Bobusoglu O, Tamer L, Karpuz D, Hallioglu O. MicroRNA values in children with rheumatic carditis: a preliminary study. *Rheumatol Int*. 2018;38(7):1199–205. <https://doi.org/10.1007/s00296-018-4069-2>.
77. Li S, Hang L, Ma Y, Wu C. Distinctive microRNA expression in early stage nasopharyngeal carcinoma patients. *J Cell Mol Med*. 2016;20(12):2259–68. <https://doi.org/10.1111/jcmm.12906>.
78. Zhao L, Zhang X, Wu Z, Huang K, Sun X, Chen H, et al. The Downregulation of MicroRNA hsa-miR-340-5p in IAV-infected A549 cells suppresses viral replication by targeting RIG-I and OAS2. *Mol Ther Nucleic Acids*. 2019;14:509–19. <https://doi.org/10.1016/j.omtn.2018.12.014>.
79. Patil KS, Basak I, Dalen I, Hoedt E, Lange J, Lunde KA, et al. Combinatory microRNA serum signatures as classifiers of Parkinson's disease. *Parkinsonism Relat Disord*. 2019. <https://doi.org/10.1016/j.parkreldis.2019.04.010>.
80. Zhang D, Liu E, Kang J, Yang X, Liu H. MiR-3613-3p affects cell proliferation and cell cycle in hepatocellular carcinoma. *Oncotarget*. 2017;8(54):93014–28. <https://doi.org/10.18632/oncotarget.21745>.
81. Ren D, Navarro B, Perez G, Jackson AC, Hsu S, Shi Q, et al. A sperm ion channel required for sperm motility and male fertility. *Nature*. 2001;413(6856):603–9. <https://doi.org/10.1038/35098027>.
82. Liu S-W, Li Y, Zou L-L, Guan Y-T, Peng S, Zheng L-X, et al. Chloride channels are involved in sperm motility and are downregulated in spermatozoa from patients with asthenozoospermia. *Asian J Androl*. 2017;19(4):418–24. <https://doi.org/10.4103/1008-682X.181816>.
83. Matzuk MM, Lamb DJ. The biology of infertility: research advances and clinical challenges. *Nat Med*. 2008;14(11):1197–213. <https://doi.org/10.1038/nm.f.1895>.
84. Papaioannou MD, Nef S. microRNAs in the testis: building up male fertility. *J Androl*. 2010;31(1):26–33. <https://doi.org/10.2164/jandrol.109.008128>.
85. Mukherjee S, Ridgeway AD, Lamb DJ. DNA mismatch repair and infertility. *Curr Opin Urol*. 2010;20(6):525–32. <https://doi.org/10.1097/MOU.0b013e32833f1c21>.
86. Pinzón N, Li B, Martinez L, Sergeeva A, Presumey J, Apparailly F, et al. microRNA target prediction programs predict many false positives. *Genome Res*. 2017;27(2):234–45.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.